Adial Pharmaceuticals announced on February 19, 2025, that the United States Patent and Trademark Office (USPTO) issued patent number 12,226,401 on February 18, 2025. This patent expands coverage of Adial’s genetic-based approach to treating and diagnosing alcohol use disorder and other drug dependencies.
The new patent covers claims focusing on a method for identifying genetic markers in patients with alcohol or opioid-related disorders. Specifically, it includes the AC genotype of rs17614942 in the HTR3B gene and the AG genotype of rs1150226 in the HTR3A gene.
This expansion allows providers to offer tailored treatment plans using AD04 based on a patient’s unique genetic profile. This personalized method is designed to deliver optimal outcomes and reduce risks associated with one-size-fits-all approaches, enhancing effectiveness for millions suffering from addiction.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.